Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials
Year: 2019
Type: editorial
Abstract: Symptomatic adverse events are common with cancer therapies, and provide key information about tolerability during development and regulatory review. After a therapy becomes available on the market, information about these adverse events is essential for patient and clinician decision-making. Historically, the standard approach for collecting symptomatic adverse events in trials depended on clinician reporting via the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events (CTCAE)—but this process was found to be unreliable and to miss about half of patients’ symptoms.
Source: Clinical Trials
Authors: Ethan Basch, Allison Barz Leahy
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W2924804309